Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
Date:11/2/2011

opment of our NS5A drug candidates.

2011 Financial Guidance
The Company expects that its current cash, cash equivalents and the anticipated royalty payments associated with product sales of Tyzeka®/Sebivo® (telbivudine) will be sufficient to satisfy its cash needs into at least the second quarter of 2012. This guidance assumes no additional milestone payments, license fees, reimbursement for development programs and no financing activities.

Operational HighlightsIDX184 Program
The Company's lead program, IDX184, is a pan-genotypic oral nucleotide polymerase inhibitor that has shown potent antiviral activity in both preclinical and clinical studies. IDX184 is a proprietary liver-targeted prodrug of 2'-methyl guanosine monophosphate with a high barrier to resistance in vitro.

In July 2011, the Company initiated enrollment of 100 HCV-infected patients into a 12-week Phase IIb clinical trial of IDX184 in combination with pegylated interferon and ribavirin. The Company will report an interim analysis from this study after the first 30 patients have completed 28 days of treatment. The Company initiated dosing of the first 20 patients, and is currently enrolling the remaining ten patients. There have been no safety signals to date. Based on the current rate of enrollment, the Company expects to complete one month dosing of the first 30 patients in December 2011, and anticipates releasing interim one month safety and antiviral activity data for the first 30 patients from the Phase IIb trial early in the first quarter of 2012.

Discovery Programs
IDX719, the Company's lead NS5A inhibitor candidate, has shown potent and broad genotypic activity. The Company expects to submit regulatory filings by year end 2011 and begin the clinical program in early 2012.

The Company's novel nucleotide program continues to make significant progress and has generated many preclinical compounds. Given the progress
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Conn. , May 22, 2013 Z-Medica, ... today it has launched the first-ever line of products ... Services. The line includes QuikClot ® EMS 4x4 ... QuikClot ® EMS Rolled Gauze™, all custom-designed to ... until they can be transported to a hospital or ...
(Date:5/22/2013)... MANALAPAN, N.J. , May 22, 2013 ... this opportunity to update shareholders about some recent company ... will expand its avenues of communication with shareholders. Integrating ... has launched a Facebook page and will post updates ... the Twitter hashtag is #medifirstusa. Says ...
(Date:5/22/2013)... May 22, 2013  Flagship Ventures, a leading ... healthcare and sustainability, today announced the appointment of ... Senior Partner. In this role, Mr. Bancel will ... In addition to working closely with ... serves as President and Chief Executive Officer of ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Medifirst Solutions, Inc. Announces Update To Shareholders 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3
... Ind., Oct. 6 Hill-Rom Holdings, Inc. (NYSE: ... unanimously approved enhancements to the Company,s corporate governance ... majority voting in uncontested elections. The Board ... a majority voting standard for the election of directors in ...
... 6 CareFusion (NYSE: CFN ), a new ... rankings by independent market research firms for two of ... named number one in user satisfaction ratings in MD ... the third consecutive quarter; and CareFusion,s MedMined(TM) Services received ...
Cached Medicine Technology:Hill-Rom Announces Corporate Governance Enhancements 2Hill-Rom Announces Corporate Governance Enhancements 3Hill-Rom Announces Corporate Governance Enhancements 4CareFusion Earns Top Ranking in MD Buyline and KLAS Reports 2CareFusion Earns Top Ranking in MD Buyline and KLAS Reports 3
(Date:5/22/2013)... France: Results from a large observational study ... bivalirudin is superior to heparin in the ... mortality in patients with non-ST segment elevation ... intervention (PCI)., European and US NSTE-ACS guidelines ... to unfractionated heparin plus GP IIb/IIIa receptor ...
(Date:5/22/2013)... 2013 The PreDiabetes Center of ... the Greater Philadelphia Tour de Cure, a premier cycling event ... passionate about stopping the spread of diabetes , a ... , The Tour de Cure will take place Saturday, June ... in Ambler, 30 minutes outside of Philadelphia, between the hours ...
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 According ... Culture, Consequences, and Cost ” article published recently at FinancesOnline.com ... fully justified. The Centers for Disease Control and Prevention ... aged 20 and over are overweight, 35.7% are obese, and ... highlighted in this investigative article. In particular, the article focuses ...
(Date:5/22/2013)... Georgia (PRWEB) May 22, 2013 ... finalists for its Better Play & Recreation Contest, ... hundreds of thousands of youth, people with disabilities, ... need of rescue. The general public is encouraged ... to help their favorite non-profit organization win the ...
(Date:5/22/2013)... City, NJ (PRWEB) May 22, 2013 ... compliance, and management solutions for social enterprise collaboration ... LLC, a consulting firm based in Chicago, Ill. ... integrate their products and provide best-in-class solutions for ... and improve collaboration. , AvePoint’s DocAve Software ...
Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3Health News:Public Voting Opens for Finalists in Synthetic Turf International’s Better Play & Recreation Contest 2Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3
... intra-aortic balloon pumps prior to angioplasty in patients with ... of heart muscle damage, a condition referred to as ... Duke University Medical Center researchers. The findings ... the American Medical Association ( JAMA ), and ...
... , MONDAY, Aug. 29 (HealthDay News) -- Although older ... may not be making good decisions about their coverage, ... -- particularly those with impaired brain function -- can ... plans available to them, preventing them from finding the ...
... , MONDAY, Aug. 29 (HealthDay News) -- The width ... performs, according to a new study. Researchers compared the ... their companies, financial performance. The study included only men because ... behavior applies only to men. The firms of CEOs ...
... agree that financial constraints and an aging population will require ... find that pushing back the eligibility age could be a ... most. The consequences both positive and negative of ... presented in the latest installment of the Public Policy & ...
... Caution is required when deciding whether to stop life support ... Researchers examined death rates after life support was ... brain injury in six trauma centers in the Canadian provinces ... the patients died in hospital, but the rate varied from ...
... EMPHASIS-HF study showed significant reductions in death and hospitalization ... failure (CHF) and mild symptoms treated with eplerenone in ... and standard therapy. Commenting on the findings presented ... Cardiology Congress (ESC) Hot Line Session on 29th August ...
Cached Medicine News:Health News:Study shows balloon pump use prior to angioplasty does not reduce heart muscle damage 2Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 2Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 3Health News:Aging authorities differ on tweaks to Social Security's benefit structure 2Health News:Use Caution in Ending Life Support for Brain-Injured, Experts Say 2Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 2Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 3
... wide range of Platelet aggregometers allows ... meet particular needs. Single, dual and ... chart recorder outputs or digital computer ... Optical aggregometers, which measure platelet aggregation ...
... The PAP-4C is a four channel platelet ... available: chromogenic assays, von Willebrand assay (Ristocetin ... PAP-4C may also be used for the ... (HIT). Four channels allow four tests to ...
Express Plus analyzer is a great choice for small and medium workloads....
Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
Medicine Products: